Molecularly engineering a dual-drug nanoassembly for self-sensitized photodynamic therapy via thioredoxin impairment and glutathione depletion

References

• Chen Y, Zhao T, Bai M, et al. (2022). Emerging small molecule-engineered hybrid nanomedicines for cancer therapy. Chem Eng J 435:135160.
   Web of Science ®Google Scholar
• Dai X, Du T, Han K. (2019). Engineering nanoparticles for optimized photodynamic therapy. ACS Biomater Sci Eng 5:6342–54.
   PubMed Web of Science ®Google Scholar
• Ding Y, Wang Y, Hu Q. (2022). Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration 2:20210106.
   Google Scholar
• Jana D, Zhao Y. (2022). Strategies for enhancing cancer chemodynamic therapy performance. Exploration 2:20210238.
   Google Scholar
• Jia D, Ma X, Lu Y, et al. (2021). ROS-responsive cyclodextrin nanoplatform for combined photodynamic therapy and chemotherapy of cancer. Chin Chem Lett 32:162–7.
   Web of Science ®Google Scholar
• Jiang J, Mei J, Ma Y, et al. (2022). Tumor hijacks macrophages and microbiota through extracellular vesicles. Exploration 2:20210144.
   Google Scholar
• Liang H, Zhou Z, Luo R, et al. (2018). Tumor-specific activated photodynamic therapy with an oxidation-regulated strategy for enhancing anti-tumor efficacy. Theranostics 8:5059–71.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen C, Wei T, et al. (2021). Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Exploration 1:21–34.
   Google Scholar
• Liu R, Luo C, Pang Z, et al. (2022). Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chin Chem Lett.
   PubMed Web of Science ®Google Scholar
• Liu X, Fan Z, Zhang L, et al. (2017). Bcl-2 inhibitor uploaded upconversion nanophotosensitizers to overcome the photodynamic therapy resistance of cancer through adjuvant intervention strategy. Biomaterials 144:73–83.
   PubMed Web of Science ®Google Scholar
• Liu X, Zheng C, Kong Y, et al. (2022). An in situ nanoparticle recombinant strategy for the enhancement of photothermal therapy. Chin Chem Lett 33:328–33.
   Web of Science ®Google Scholar
• Liu Y, Zhang J, Guo Y, et al. (2022). Drug-grafted DNA as a novel chemogene for targeted combinatorial cancer therapy. Exploration 2:20210172.
   Google Scholar
• Shan X, Zhao Z, Wang C, et al. (2022). Emerging prodrug-engineered nanomedicines for synergistic chemo-phototherapy. Chem Eng J 442:136383.
   Web of Science ®Google Scholar
• Song L, Li J, Xie S, et al. (2012). Thioredoxin glutathione reductase as a novel drug target: evidence from Schistosoma japonicum. PLoS One 7:e31456.
   PubMed Web of Science ®Google Scholar
• Wang C, Yu H, Yang X, et al. (2022). Elaborately engineering of a dual-drug co-assembled nanomedicine for boosting immunogenic cell death and enhancing triple negative breast cancer treatment. Asian J Pharm Sci 17:412–24.
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun M, Li D, et al. (2020). Cytochrome P450 enzyme-mediated auto-enhanced photodynamic cancer therapy of co-nanoassembly between clopidogrel and photosensitizer. Theranostics 10:5550–64.
   PubMed Web of Science ®Google Scholar
• Weir GM, Liwski RS, Mansour M. (2011). Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) 3:3114–42.
   PubMedGoogle Scholar
• Xie J, Wang Y, Choi W, et al. (2021). Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies. Chem Soc Rev 50:9152–201.
   PubMed Web of Science ®Google Scholar
• Yang F, Ji Q, Liao R, et al. (2022). Precisely engineering a dual-drug cooperative nanoassembly for proteasome inhibition-potentiated photodynamic therapy. Chin Chem Lett 33:1927–32.
   Web of Science ®Google Scholar
• Yang F, Zhao Z, Sun B, et al. (2020). Nanotherapeutics for antimetastatic treatment. Trends Cancer 6:645–59.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wu H, Liu B, Liu Z. (2021). Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. Adv Drug Deliv Rev 179:114004.
   PubMed Web of Science ®Google Scholar
• Yu J, Chu C, Wu Y, et al. (2021). The phototherapy toward corneal neovascularization elimination: An efficient, selective and safe strategy. Chin Chem Lett 32:99–101.
   Web of Science ®Google Scholar
• Yu L, Wang Z, Mo Z, et al. (2021). Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Acta Pharm Sin B 11:2004–15.
   PubMed Web of Science ®Google Scholar
• Yu W, Shevtsov M, Chen X, Gao H. (2020). Advances in aggregatable nanoparticles for tumor-targeted drug delivery. Chin Chem Lett 31:1366–74.
   Web of Science ®Google Scholar
• Zhang S, Sun X, Wang Z, et al. (2022). Molecularly self-engineered nanoamplifier for boosting photodynamic therapy via cascade oxygen elevation and lipid ROS accumulation. ACS Appl Mater Interfaces 14:38497–505.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Kong Z, et al. (2022). Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy. Biomaterials 282:121433.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Y, Kong Z, et al. (2021a). Pure photosensitizer-driven nanoassembly with core-matched PEGylation for imaging-guided photodynamic therapy. Acta Pharm Sin B 11:3636–47.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Z, Kong Z, et al. (2021b). Photosensitizer-driven nanoassemblies of homodimeric prodrug for self-enhancing activation and synergistic chemo-photodynamic therapy. Theranostics 11:6019–32.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li N, Zhang S, et al. (2020). Emerging carrier-free nanosystems based on molecular self-assembly of pure drugs for cancer therapy. Med Res Rev 40:1754–75.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Song J, Nie L, Chen X. (2016). Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. Chem Soc Rev 45:6597–626.
   PubMed Web of Science ®Google Scholar